Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 5, 2011, Pages 700-711

  Sato, Jun ^a   Kimura, Takashi ^a   Saito, Takuro ^a   Anazawa, Takayuki ^a   Kenjo, Akira ^a   Sato, Yoshihiro ^a   Tsuchiya, Takao ^a   Gotoh, Mitsukazu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Gemcitabine; p53R2; Resistance; Ribonucleotide reductase

Indexed keywords

GEMCITABINE; GLUTATHIONE; MESSENGER RNA; PYRIMIDINE; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASES; RNA, NEOPLASM;

EID: 80052535410     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0376-7     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225-49.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-25. (Pubitemid 38738341)
3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303-14. (Pubitemid 41416587)
4. Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. 2007;61:44-51. (Pubitemid 44880150)
5. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;66:167-79. (Pubitemid 38813042)
6. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9:43-57. (Pubitemid 38134013)
7. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896-902. (Pubitemid 46452283)
8. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3: 415-24. (Pubitemid 36958272)
9. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995;22:11-8.
10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3-10.
11. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349-57. (Pubitemid 28450036)
12. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004;95:753-7. (Pubitemid 39335096)
13. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009;69:178-84.
14. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492-7.
15. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol. 2007;25:32-42. (Pubitemid 350003048)
16. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64:3761-6. (Pubitemid 38697284)
17. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999;59:4204-7. (Pubitemid 29418726)
18. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Intl J Cancer. 2007;120:1355-63.
19. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004;23:1539-48. (Pubitemid 38406516)
20. Zhou B, Mi S, Mo X, Shih J, Tsai J, Hu E, et al. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res. 2002;22:1369-77.
21. Raphael M, John RM, Raymond L, Pieter D, Marc P, Marc P, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant Gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15:2913-9.
22. Jose GM, Miriam MA, Javier FC, Adela M, Marcal PA. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 20,20-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000-8.
23. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22:7369-75.
24. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-43. (Pubitemid 41131715)